BD Medical, a segment of BD (Becton, Dickinson and Company), a leading global medical technology company, announced that the US Food and Drug Administration (FDA) has cleared the BD Intelliport Medication Management System, the first-of-its-kind medication management solution for manual IV bolus injections.
The Intelliport System is the first and only solution to provide real-time drug identification, dose measurement and allergy detection at the point of injection, while wirelessly sending captured information directly into the patient’s electronic medical record (EMR) following medication administration.
With this new FDA clearance, BD can offer healthcare workers advanced, smart-injection-site functionality and access to medication administration information at the point-of-care.
By combining the Intelliport System’s unique IV access site sensor with a rechargeable, wireless base and touch-screen tablet technology, integrated with hospital information systems, essential medical information can be recorded instantaneously, following patients throughout their perioperative stay. The Intelliport System is expected to be commercially available in spring 2015.
"As medication errors remain a primary concern with healthcare providers today, the FDA’s clearance of the Intelliport System offers a significant step forward in enhancing patient safety, while also improving workflow efficiencies," said William A. Tozzi, President, BD Medical – Medical Surgical Systems.
"BD has always supported healthcare providers in their efforts to exceed compliance standards and provide quality patient care and the Intelliport System is yet another example of how we bring that commitment to life."
The first live demonstration of the Intelliport System since receiving FDA clearance will be held during the Society for Technology in Anesthesia (STA) 2015 Annual Meeting taking place January 7-10 at the Royal Palms Resort in Phoenix, Arizona.